RxPreferred to Offer Yusimry Through Mark Cuban's Online Pharmacy
The Humira biosimilar is a tumor necrosis factor (TNF) blocker and was approved by the FDA in 2021.
RxPreferred, a pharmacy benefits administrator, will offer the Humira biosimilar Yusimry through Mark Cuban Cost Plus Drug Company (Cost Plus Drugs). Beginning July 2023, RxPreferred members will have access to Yusimry (adalimumab-aqvh) for $569.27 plus dispensing and shipping fees. This price represents a 92% discount from the Humira list price, improving both the affordability and accessibility of treatment options for patients. The list price of Humira is $6,922.62 as of January 2023.
Yusimry, approved by the FDA in 2021, is a tumor necrosis factor (TNF) blocker to treat patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.
RxPreferred is the second PBM to offer Coherus BioSciences’ Yusimry, which recently launched with a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors. Last month, SmithRx announced that it would Yusimry through Mark Cuban’s online mail-order pharmacy for $569.27 plus dispensing and shipping fees. SmithRx members will also be able to apply their insurance benefits.
RxPreferred teamed up Cost Plus Drugs in January 2023 provide its members with access to all medications available through the online pharmacy.
“Our relationship with RxPreferred has already begun to make an impact, helping individuals and families with medication affordability," Alex Oshmyansky, chief executive officer of Cost Plus Drugs said in a press release.1 “This is an evolutionary process, and this announcement (about Yusimry) is the type of progress we had hoped for and the reason we started this company.”
Headquartered in Nashville, RxPreferred is privately-held and operates nationally, also offering a variety of pharmacy solutions including 340b administration and PBM services for hospice, long-term care, and workers’ compensation.
This article originally appeared on Formulary Watch.
